Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOR3VTUUlJaHRRSnlEeHJhdFdvOC1YdHl5OUNRQ2R4VTR1bk1UVXBDMm4zOFdPTG1acG14S3drWmxTSWRickZZaFAtTGRsQ1gyYmxiZ3BGOUItbzQ3LTZ6QUlFQUtIbW1kVkY3TWRfb0xxYi02MVAxci11ZUFDdndvU1BWdEh2R2dmc2lzYUdnMEI3SDJK?oc=5" target="_blank">Exploring the Shifting Treatment Paradigm for Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Hematology Advisor</font>
Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
Levante - Sevilla en directo
"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon
Indigo Girls cancel show after tour bus driver dies in highway crash
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB6M05yNGVnUlRrSWY0SE1fZlVlNGlwQzFEemNoVDE0WkN3bU1NMEJEb0JhckhNU28zYUlscVdpYUNobE50OVJLY3dFb2VJemR0czdYRGRJM3BnLTQ5X2tB?oc=5" target="_blank">Redefining light-chain smoldering multiple myeloma: prevalence and progression risk</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPTjBVREt3Sm13c29Xd1hmZE45Wk10TjZCZDN5T0xFbTRXa3l2V2Z1dmJhbzh5VlVUaFBJcXVRNjRFNm1sODN2WXVrWDVGeXJhN1JVa0RxR3JNYUFVUnVJWFBSdE90bnVrbk85b1NySzRZbTBTM1hlUV8tVXhkbGZCTFJ3Q25uOTNjMHc?oc=5" target="_blank">Bloodlines Series: What Is Smoldering Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">American Association for Cancer Research (AACR)</font>
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE55a09WLWVFMGR6TG1NNGFmMDBqUnZ5cS0wUllTOEVldklERjN6a2g4SUlHRW1vYXY4XzMxMUI4T0FfWmhMR3lfdjBfS3Z0ejRpaFdZektBMGdhWVBPcUlRZTZiM0ZyNmV1RXc?oc=5" target="_blank">What You Should Know About Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Health.com</font>
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQXzd0eERMUUxPWUNqZHIzZ3F3QTF5Vjc1T0RTVi1YUDFTQmhEOUxyck9zTjY3UUNQUFNfcEZwcHpKNFNLNkVFNjJFay1FSm93czU1Z1AxMl8wSk5FeS1MbDlTQnVobUZ1c2ZVOGJqRnRCcGk0ZlNsWjRYTEkxRWt5MTJEWUVKR203MXk2T1VGX3B6QVdHTzBvXw?oc=5" target="_blank">Linvoseltamab in Smoldering Myeloma: Fewer Doses, Less Risk?</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPUG5vNDBwU2JfNjJJUzFRN29qTFFoejRwTFZkVTlLOHh5SVZ6bS1HYUtlNGZrZ1BGZ1FYMnNCWWNhU3p4blQzemNDUndRT3VxVE5WVzZabzc2Rmd5UHZTMS1makdWci15SXVkZ1c5ZjlKR1RtMEZCdG0yaVo5cnpmRV9rbHpHZWhpb0ExaVFOQXNCeWl0TVFlWlNudEE4ZDhzRVpB?oc=5" target="_blank">Smoldering Myeloma: The Treatment Issue Is Getting Trickier</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPZnIydWJ2QzlmeVlCX1JfNGJieXBiMm5CenhKcGRlQXZGS054WDZLMnNmZnNyeE9wOEJmMlM0SkJkZnBaYlhmdEFzMUU5Y2JQSXdvdXpGWGtMWjh6ZmQ4WXF1cDRpUXJVNkVvNVQ5RXN6d0thaGlBX3hJTXA0eHlydl9lLWZHaHQ1NUMzLWtXanlaOVJ5SzZ0SnZZdWYyOVNLV242UGk2UmtuNzdvRF9z?oc=5" target="_blank">Quadruplet Combo Appears Effective in High-Risk Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNSGpxTWtseEZlN3ZKOTBSNER6LU1MLUNmR1NrcE93bEJsbVBnRHdQZ2ZDQS0yYXgwQlI2SWJuM2lwaWhmVEhiQWN0bUJCVHpBd0NUQlpJdmJoWGtKZXRUcXFQNjQzY0FTVHVRQ0FnSXNXLU00X1laR05LODdsb2JJRFNib3FkZmpQNWlYeGEtdw?oc=5" target="_blank">When Should Oncologists Treat Smoldering Multiple Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">ASCO Daily News</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYlF3R25lcV9JanBzS1JibHBKaUdRNnVDX0RpOHFPc1dBR19RRXVva0tXUHlSdTNZVjRuM2FjQ0tENnlScnNXVmtfRjVhTXFZYVllcWR0UnlEcmpkX2libG8zZncyRF9vRURDMFpzS3ZrZ2pSODdmNFNtWlIwbHFVZFJnM1kxYm90VmtiN2ZCV25oUC12MEJaUzhxbVFQcjZudEJsaE1Kc1NfZkxIWTVXTmY4MTF0ODNLdVJ0ckdDaXo?oc=5" target="_blank">High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxONHhHSWhUbjdmelUzM2xhbWJMQW1oUXVsZmpNalItWUdvdUpSUXlja3Vuc3dDVnAzNDVmM2dwZlRTQXdMR04yLVM0eWxHN0k2ZF8tX2N6SE5Xc2dNWk1GUmszaEdrRTZCNlBiQUNsYWZ6NEJmVEJtMkRtMGNyQ3p5VUQ2Q0dIYUlUNUdkZlZNeGdoLXhzVVNUTmhfUmJuMWx0czZEVk5MQ3NVb2F5QzU4?oc=5" target="_blank">Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOMXA2VW9OclVtQnhWckR4c1hkWFB3STU1ZTZGVWs5UFJnN2hVZWwzeEJzSm5mZzZEYzdwUzlHZndGU09sZTNQQVF1am9DQ3pXUXZ0WnhQbUtHOVE4SFcwQ1NDblZQNG8xMk1famhGM3FvUUpMZWxwNm93V1N5TVZ6WU1GcEI1TzVNdlZhRS1VWFJBVTlWcllsVzRsRnlqeDVyTXlHZw?oc=5" target="_blank">Could MGUS Screening Change the Trajectory of Multiple Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">Cancer Nursing Today</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBFWEhuVFc2RHBxWmlfMEkwdGVxdUJlX0RJOU9GQjBEQjJRZFc5dEJyNDZna3Z2ZWtHSlFkTndXa3JNX3JBLWkzR2ROdWtCSHg5NWVadU5wbkpMS2d2azJJ?oc=5" target="_blank">Smoldering multiple myeloma in transition: redefining early myeloma in the modern era</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTC1tMXJVSUFsVVZCWUx4dTN2azVLVW9UUEIzdTZhanNpQXBwbnBwT3VDU2dXQ3A0SDVtNTlKbnhxUEh3c3N5VTlWQngwdksxZDNfYkJsLUtCekpuM1BGVXJCR2hlZVo2OFJFYU5qdG5XclVIWTk1Z2dXallNcUxXcW9keGRZVlBCdTE3MzZWbElCNVQyRVctc21OZUo1T09rVjBDeHZCVVM?oc=5" target="_blank">Linvoseltamab in Smoldering Myeloma: Is Early Treatment Worth the Risk?</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQT1k3clBaUUFFbloySHd3UkZWcGtNS3NMaHpyY1dkU2swc1VnNEV3VEhVTkY4MXFWcjEzbnBxNFRmTnhpNVV4aTk1cWhjZjh5R2ZrQmUyY2Q2YWxheElMRUF1eXFuRmY5M2hZd1VzQUdqQS1qOFhlYjVrdkRoR1BkOFVCNTlDdTAyYkJjY1IyS3p4Z1RuaFBBR2tuX3RJNVloc1JtWDZFd3M5dFF4cHU0?oc=5" target="_blank">Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQRFVkZmJQYVJEcmxqMlJLY2x4alpEN3NhbFVyWGk2Wld2RXpNbGNHSnI2VEhWT1F0aTdjcGY4TEJ4elVaeEpaVXprRnlxUl9HdmtHbUZsUzVFaHBWVHFvT2ktLW1obndSNHMyZWlBRExSdW84UHR6SVpWVzFaaWFCRk9XRVRPTnNNRGxFTXhqMEF6cDdTNlF1cTNZZkotMFVtRnc?oc=5" target="_blank">Why Surveillance Remains a Valid Choice for High-Risk Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">ASCO Daily News</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNZk1nWEpWUGlOTnNjbVN4T0V0VjdLZmJaVF9nRm1fUzlZbEplM2dVOU5mVU13SEZkYXFOUTB4SWRNTlFuN2M4VEs1WndRVDVHa19fOW9URUxRekNrWkhZ?oc=5" target="_blank">Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNnlBQVlJR21aaGxwb2czS0lSaWZENGFpVWV5VEs0YjZuSG5aS0pjNHFVRThwNUVJT2tQQTVlNEVGSDA5cHhFYVd5THYyaXZuV0V1aGN4Rk0zbEt3MGhaTlVyckxQbzJMYzQtRmhCQnRUS2lGakRONk5NZ2dqYzhpSTNkS1Rfd0tCRWtYVmtVTk82VXhZMy1RSUtyeXNudTM3XzM1S1NUcmo2UQ?oc=5" target="_blank">Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HUjF1MXo4U0lPckpRNWZjclpIMjRmb29kd2xkbXhtOGYteV9SSEI3OTlkcm9WVjJrcUFFaG1oZGRNeTlmNVVWR1dlRWpUc1RzNzV2RTdOamY5czRIVW04?oc=5" target="_blank">Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0EzdXJMY0pITHNCS28xTHhkM1hVblJnS3dIMFJoakNIVmJucGlPQ1g5MVplUnJaWDNfZDRfdC1VbXdlazZKS05MZDdnODFWemVIOEVzeVZxeDl1bFlLcWduQkZxUHZzX053b3dkRnktWVNiRm1ySXdXUDRqVHZSbDM5SzYybHhETGxRYmlKOE4wa0NEQlBxQkxYTUxEQkl6ZWZvNWdKdHFWYUhwM3E4R0ZLd3hRVm1FUHh4YkhvMTRfYTljN3RZbA?oc=5" target="_blank">Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1CZGNvSnhTXzNLMHU0T3U0eE1vQjl0VUticTZqYWpHWlRRYXJxY1JiVEp6Q1hVeXJQSnNEdWs3UnJLel9NSllyTnZXOXZHZUlqd3NXUlJVUEJSelRibUNj?oc=5" target="_blank">Enhanced dynamic risk stratification of smoldering multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbm5abFk5Q09ZN1htbUthYTBIZUFJbGFwZ1c0cW5uRXhXUmd2c0tENm1kQk5ESS1BcjdIZjEzVEpVUVhIWENocVg4ODBVMkd4N01kUzVKVjlNVXFfUm1rQy1MQXZPSFRfUnpremM0alZsQ1hOeU52ampsVlFGWWNYaEhYX0tFbzBza2dZam9sUjcwSUlVaVY5aWZFVUtGTDRpcmhpcWtiWmw?oc=5" target="_blank">How Has SC Daratumumab Affected Smoldering Multiple Myeloma Treatment?</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQZDdWQ3JKZDlsSjhrNFpDY1B0eU02cV81N19ncmViUGpKOWliNE5fWk5pbERIeEN4QWQwNFpxMkRtdDdPaDFqRXdXNnNyV0NtbHdXSnR6YnQyTllubnZPU3ktcXVhOXZsTkNLTURYWl9jM1JGZXNlamtOS0lJS25FU1l0Z3JzMUN0SERXbDlGUjRDZTRfNGwyNERsQzhGX2RldTBvUDJmUGxOOUhvVmc?oc=5" target="_blank">Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNekxrLWswU2k5OWhULVo2UDdQc2tRSGxINHhoclRkY0ltWVZnTzNWc1RCUGU5QnlmSFlzUzR1dkhKanNST3ZqZDVBWGpUeWlqOUFsN3RYdTA2TnB5aFFxbVp5ZElwQm9HS1JibjF5SFU4WGNrRXZBUXRTcWxTaGtXRWxyc0l6R1pTTlJKeG1BNDdOTVpMYm1DUENiQTNCZVU2OHpVMUo4Q1k?oc=5" target="_blank">Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9HaDRmUVVtR2lORVJudDZaUTladlBtZUxzSWdtV1VGZS1vWHRlb3lDOWhKLUtZSkwxOVp3TkhvVVV2NTZJYWlndGhZTWVKNWZoM3ptMk53Zm1BYWVCN3FF?oc=5" target="_blank">A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1mUGxveWh1ZGZiNEVqb3RFT2k1OHdmUjRVS1pXeXJuTkIxVER1WkotV2RBQUl5YVRmZGxzTDZIdGNoY0c0LXRQaUdSYnN4dXNweHFPX2NGZkRNWEVBb2Zz?oc=5" target="_blank">Diagnosis, risk stratification and management of smouldering multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOU1lHaXVSUnl5Zi1xQ05QS2Y1Z2pjN3lKRzBCNTM3SWRVTFpzNEJMSXN5dXNwR1p1REk4LUFoWUNsY3dTQVY2c3E4SE52MUcydzVXMXcwcWx5SnRPVzZuTEg0cUxUSkVMS2xYYkNLVVhnT3VVTm53U1RzTXptLU12RFZGYUE3ZnQwSkJsZVZ3eVNmenNHWXNhTTdZUDhvTDBIOHI3TG8yYUZObzBpX3Uza2czeVl6Y29FQ09UMGwtV1FoOXVlWTFYVUZ3?oc=5" target="_blank">Linvoseltamab Shows 100% Response Rate in Smoldering Myeloma, Raising Early-Intervention Question</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNMEJId0VLeVNjZ1JPODBEQlQweC1ZY0R3UDFLS0JRLTZwQ3dKVm1JZkU4WW9DZ0N6Tmp1aUV2VDZIVkRGQmYtb1RCYURKbjltRmZCR3JvaFc4RVFEV2dST1l4NWpSM05nZ2JBa24zSkdvbmRvTHJwdHcxeFcxdWIyTFY5aW9JNmkySXFvXzhnZUEwY3VSTWxQWTVwX1RRSTJuX2oyVDNTcWg1azBjUkRNdUQ5VmEzczR0cVhXaDU0cWZ5VWo0V0Z5aElOSmN0SjgzS0lwcE5KVnNuV1dB?oc=5" target="_blank">EHA 2026: Early intervention with teclistamab achieves deep remissions for high-risk smoldering multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology Central</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5BRkJSd09lWl91alZYMDJUeE9vUmtVQl9tZmxzdnB5Y25NVWJTdTBNaXdSYV96OGFTbFNFZ3R1Y0NROTQ2T2JGSHVONTAwd25WVUZOTkFGUnE0bm9Tdy1N?oc=5" target="_blank">Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQbVlTNUl1TlQxMm1pY0NrRGt4cG4yN3NYNVVNZXJkdUZ3Z011ZFF3X18xNVdZQzA1SmUxVjM5dFlJYUpoZ1lOR2tHX3A3V01MMEF2MmhnUE14MkZrSWduenNDeFIwLWxlUlc3aDY4QW9HVHlfTVFDTVB0OENGZXZYSk1pYnd1NVIwTDhLc21fMldYMWMzNzZwdHhZalgtenN4cmxBNUpNMjhQUmR1?oc=5" target="_blank">Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3lEUUNlZGJtV3VKczEzV1JzM1ZjZEVTRmJKV3I5Y01QZDhaWjVydVd5UUdOSC1jb3FpN3VFRTYyR3ZOb0pSWEpwMm10dnJlMTZNOTU0N2NsVzctRVdnbzR3d2ZJU01xMnZEbzhVbzRad2RBaEFKMjlveGVWZ3pmMVdQQ2hwZURBcTZCSHJ4MUtudw?oc=5" target="_blank">Exploring a New Era of Treatment for Smoldering Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>